المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty

المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline

المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test

المؤلفون: Céleste Lebbé, Anna Maria Di Giacomo, Helen Gogas, Georgina V. Long, Paolo A. Ascierto, Catalin Mihalcioiu, Francesco Cognetti, Ewa Kalinka-Warzocha, Kerry J. Savage, Cornelia Mauch, Ana Arance, Jasmine I. Rizzo, Lars Ny, Caroline Dutriaux, Piotr Rutkowski, Caroline Robert, Micaela Hernberg, Victoria Atkinson, Vanna Chiarion-Sileni, Benjamin Brady, Inge Marie Svane, Dirk Schadendorf, Jessica C. Hassel, Julie Charles, Laurent Mortier, Catriona M. McNeil, Abdel Saci, Joel Jiang

المصدر: JAMA Oncol

مصطلحات موضوعية: advanced melanoma, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Adolescent, Dacarbazine, Medizin, Phases of clinical research, Ipilimumab, Pembrolizumab, Placebo, BRAF, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Nivolumab, wild-type, Antineoplastic Agents, Alkylating, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Correction, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c9b0d0b1e4e0e7e07096a725b4e567Test
https://doi.org/10.1001/jamaoncol.2018.4514Test

المؤلفون: Victoria Atkinson, Céleste Lebbé, Jessica C. Hassel, Catalin Mihalcioiu, Cornelia Mauch, Ewa Kalinka-Warzocha, Ian M. Waxman, Ana Arance, Piotr Rutkowski, Kerry J. Savage, Vanna Chiarion-Sileni, Caroline Dutriaux, Micaela Hernberg, Abstr Act, Laurent Mortier, Catriona M. McNeil, Brian Sharkey, Caroline Robert, Dirk Schadendorf, Michele Maio, Christine Horak, Georgina V. Long, Lotta Lundgren-Eriksson, Benjamin Brady, Helen Gogas, Francesco Cognetti, Henrik Schmidt, Paolo A. Ascierto, Julie Charles

المصدر: Robert, C, Long, G V, Brady, B, Dutriaux, C, Maio, M, Mortier, L, Hassel, J C, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Savage, K J, Hernberg, M M, Lebbé, C, Charles, J, Mihalcioiu, C, Chiarion-Sileni, V, Mauch, C, Cognetti, F, Arance, A, Schmidt, H, Schadendorf, D, Gogas, H, Lundgren-Eriksson, L, Horak, C, Sharkey, B, Waxman, I M, Atkinson, V & Ascierto, P A 2015, ' Nivolumab in previously untreated melanoma without BRAF mutation ', The New England Journal of Medicine, vol. 372, no. 4, pp. 320-30 . https://doi.org/10.1056/NEJMoa1412082Test
New England Journal of Medicine; 372(4), pp 320-330 (2015)

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Dacarbazine, Programmed Cell Death 1 Receptor, Medizin, Phases of clinical research, Ipilimumab, Antineoplastic Agents, Pembrolizumab, ipilimumab-refractory metastatic melanoma, Gastroenterology, Disease-Free Survival, Young Adult, Double-Blind Method, Nivolumab, melanoma, ipilimumab-refractory metastatic melanoma, Internal medicine, Medicine, Humans, Survival rate, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Surgery, Survival Rate, Nivolumab, Cancer and Oncology, Female, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07253c758028e0b62a420832a391b6ecTest
https://pubmed.ncbi.nlm.nih.gov/25511188Test

المؤلفون: Kerstin Trunzer, Antoni Ribas, C. Lebbé, Dirk Schadendorf, Paul B. Chapman, Jeffrey A. Sosman, Axel Hauschild, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, Grant A. McArthur, Michele Maio, John M. Kirkwood, Thomas Jouary, Brigitte Dréno, Alexander M.M. Eggermont, John B. A. G. Haanen, James Larkin, Claus Garbe, Reinhard Dummer, Ivor Caro, Ming Yin, Paul Lorigan, Stephen J O'Day, Suzanne Cheng, David Hogg, Keith T. Flaherty, Caroline Robert

المساهمون: University of Zurich, McArthur, Grant A

المصدر: The Lancet. Oncology, vol 15, iss 3

مصطلحات موضوعية: Male, Indoles, Medizin, Gastroenterology, chemistry.chemical_compound, Vemurafenib, Melanoma, Cancer, Sulfonamides, education.field_of_study, Hazard ratio, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Dacarbazine, Oncology, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Population, 610 Medicine & health, Disease-Free Survival, Clinical Research, Internal medicine, Genetics, medicine, Humans, Oncology & Carcinogenesis, education, Protein Kinase Inhibitors, Aged, Cobimetinib, Performance status, business.industry, Prevention, medicine.disease, Surgery, Good Health and Well Being, chemistry, Mutation, business, Follow-Up Studies

وصف الملف: 573_McArthur_GA_et_al._-_Lancet_Oncol_2014.pdf - application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4Test
http://hdl.handle.net/11365/1081256Test

المؤلفون: Marta Nyakas, Stuart Spencer, Mireille Cantarini, Reinhard Dummer, Gabriella Liszkay, Paul Lorigan, Ana Arance, Caroline Robert, Mark R. Middleton, Dirk Schadendorf, Ralf Gutzmer, Kevin B. Kim

المساهمون: University of Zurich, Robert, Caroline

مصطلحات موضوعية: Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, DNA Mutational Analysis, Medizin, Phases of clinical research, Kaplan-Meier Estimate, Gastroenterology, Antineoplastic Combined Chemotherapy Protocols, Melanoma, 10177 Dermatology Clinic, Middle Aged, Dacarbazine, Europe, Phenotype, Treatment Outcome, Oncology, Tolerability, Female, 2730 Oncology, Brazil, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Neutropenia, Placebo, Disease-Free Survival, Drug Administration Schedule, Double-Blind Method, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Antineoplastic Agents, Alkylating, Protein Kinase Inhibitors, Aged, Proportional Hazards Models, Chemotherapy, Intention-to-treat analysis, business.industry, medicine.disease, United States, Surgery, Logistic Models, Mutation, Selumetinib, Neoplasms, Unknown Primary, Benzimidazoles, business

وصف الملف: 555_Robert_C_et_al._-_Lancet_Oncol_2013.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c63162f2b90b77be9846693c33b4197Test
https://www.ncbi.nlm.nih.gov/pubmed/23735514Test

المؤلفون: Keith T, Flaherty, Caroline, Robert, Peter, Hersey, Paul, Nathan, Claus, Garbe, Mohammed, Milhem, Lev V, Demidov, Jessica C, Hassel, Piotr, Rutkowski, Peter, Mohr, Reinhard, Dummer, Uwe, Trefzer, James M G, Larkin, Jochen, Utikal, Brigitte, Dreno, Marta, Nyakas, Mark R, Middleton, Jürgen C, Becker, Michelle, Casey, Laurie J, Sherman, Frank S, Wu, Daniele, Ouellet, Anne-Marie, Martin, Kiran, Patel, Dirk, Schadendorf, Mary, Richardson

المصدر: The New England journal of medicine. 367(2)

مصطلحات موضوعية: Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Dacarbazine, MAP Kinase Kinase 2, Medizin, MAP Kinase Kinase 1, Antineoplastic Agents, Kaplan-Meier Estimate, Pyrimidinones, Disease-Free Survival, chemistry.chemical_compound, Young Adult, Internal medicine, medicine, Humans, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Trametinib, Cobimetinib, Aged, 80 and over, business.industry, MEK inhibitor, Hazard ratio, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Intention to Treat Analysis, chemistry, Mutation, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778f247f586f7abe700c37ec7f75715aTest
http://ora.ox.ac.uk/objects/uuid:17a4cd0c-72ea-46f7-ab36-457c375b3557Test